Market Opportunities - The epilepsy market presents a significant opportunity, with approximately 3,000,000 patients in the U.S. and an estimated annual cost of $15.5 billion[30] - The chronic back pain market, particularly through spinal cord stimulation (SCS), is valued at approximately $2.5 to $3 billion globally[36] - The total market for Basivertebral Nerve Ablation (BVNA) procedures in the U.S. is estimated at around $100 million per year, with over 10,000 procedures performed annually[40] - The Parkinson's disease market includes around 1,000,000 patients in the U.S., with 60,000 new diagnoses each year, highlighting a significant treatment need[42] - The company is developing a drug delivery system that has already been ordered by a large biopharmaceutical company, representing a new market opportunity exceeding $50 million[41] Product Development and Regulatory Approvals - The company has received 510(k) clearance for four devices, including the Evo Cortical and OneRF Brain Ablation System, enhancing its product portfolio for brain-related conditions[23] - The OneRF TN Ablation System features a "first-of-its-kind" multi-contact RF probe, potentially reducing procedural time and improving patient safety[25] - The company is pursuing FDA clearance for a new drug delivery device intended for neurological therapies, which could expand its market reach significantly[27] - The company is pursuing a 510(k) clearance with the FDA for its drug delivery system and BVNA product[54] - Four products have received 510(k) clearance from the FDA: Evo Cortical, Evo sEEG, OneRF Ablation System, and OneRF TN Ablation System, while other products are still under development[173] Financial Performance and Funding - In fiscal 2025, the company generated approximately $9.1 million in product revenue from the Evo Cortical, Evo sEEG, and OneRF Brain Ablation System[50] - The company raised approximately $8.2 million from the sale of 16 million shares at $0.50 per share in April 2025[70] - As of September 30, 2025, the company had an accumulated deficit of $78.6 million, primarily due to expenses from operations and research and development programs[144] - The company has incurred significant operating losses since inception and does not expect to achieve profitability in the foreseeable future[145] - The company had cash and cash equivalents of approximately $6.6 million as of September 30, 2025, which is insufficient to fund ongoing operating expenses[156] Competition and Market Dynamics - The company faces competition in the epilepsy diagnosis market from Ad-Tech Medical Instrument Corporation, PMT Corporation, and Dixi Medical, among others[84] - The market for trigeminal neuralgia treatment includes competition from Boston Scientific and Avanos RF ablation systems[87] - The company faces significant competition from established players in the medical device industry, which may impact market acceptance[212] - Competitors may have advantages such as more experienced sales forces, greater name recognition, and established distribution networks[215] - The company may face challenges in developing and commercializing new products due to competition and market dynamics[214] Regulatory Compliance and Risks - The company is subject to extensive governmental regulation, and failure to comply could adversely affect its business[146] - The FDA classifies medical devices into three classes (I, II, III) based on risk, with Class III requiring the most regulatory control and typically a Premarket Approval (PMA) process[108] - Non-compliance with regulatory requirements can lead to significant consequences, including product recalls, fines, and potential criminal prosecution[128] - The PMA approval process can be lengthy and costly, with many devices never receiving approval despite applications being submitted[120] - Regulatory compliance and scrutiny will continue to be a significant responsibility for the company, even after obtaining product approvals[181] Research and Development - Research and development expenses for the years ended September 30, 2025, and 2024 were $5.0 million and $5.1 million, respectively, indicating a slight decrease[82] - The company is focused on developing comprehensive neuromodulation solutions for neurological disorders, including epilepsy and Parkinson's disease[148] - Clinical testing for new products is expensive and time-consuming, with potential delays impacting the ability to generate revenue[174] - The company may need to conduct additional clinical trials or testing, which could delay marketing approval for its technologies[177] - The company is exploring partnerships for drug delivery systems capable of therapy delivery and monitoring for up to 30 days[50] Intellectual Property and Partnerships - The patent estate includes multiple issued patents and pending applications, with expiration dates ranging from 2028 to 2045, highlighting the importance of intellectual property protection[94] - The partnership with Mayo is crucial for licensing know-how for the development and commercialization of technology, and its termination would harm the business[221] - The Mayo Development Agreement includes exclusive licensing of certain improvements and non-exclusive licensing of thin film electrode technology know-how[221] Operational Challenges - The company relies on reimbursement from private third-party healthcare payors and Medicare, which is critical for its success, but future coverage levels are uncertain[74] - The company relies on a limited number of third-party suppliers for components, which exposes it to risks related to pricing, availability, and quality[168] - The inability to obtain a supply of components and raw materials could materially adversely affect the company's business and financial condition[163] - The company faces fierce competition in recruiting and retaining qualified personnel, which could harm business if competitors are more successful[216] - The company has faced substantial doubt about its ability to continue as a going concern due to ongoing losses and negative cash flows from operations[156]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 30, 2025. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-10843 CSP Inc. (Exact name of Registrant as specified in its Charter) Massachusetts 04-2441294 (State or other jurisdiction of ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 1, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number 0-23071 THE CHILDREN'S PLACE, INC. (Exact name of registrant as specified in its chart ...

Technology and Development - The company has a proprietary FHAB® technology platform designed to enhance drug accumulation in tumors and extend the duration of activity in the body, with a U.S. patent received in June 2021[13]. - The proprietary FHAB technology allows for the production of compounds with extended serum half-lives and improved tissue accumulation compared to naked recombinant cytokines[44]. - Preclinical studies indicated that mIL12-FHAB achieved a 30-to-50-fold increase in tumor reduction compared to standalone mIL-12 in mouse models[53]. - Biodistribution studies indicated that mIL12-FHAB had 2.5-4.7 times higher tumor accumulation compared to mIL-12, suggesting enhanced targeting[63]. - The company is exploring amino acid modifications to IL-18 to enhance its therapeutic potential against cancer[110]. Clinical Trials and Programs - The lead asset, SON-1010, is in clinical development for solid tumors, with a completed non-human primate toxicity study and FDA clearance for the IND application in March 2022[16]. - In the Phase 1 SB101 trial, clinical benefit was observed in 48% of patients overall and 83% at the highest dose of 1200 ng/kg, with one patient showing a partial response[20]. - The company has dosed 103 patients and healthy volunteers with SON-1010 across three Phase 1 studies, with no dose-limiting toxicity reported[22]. - A collaboration with Roche for the clinical evaluation of SON-1010 in combination with atezolizumab is ongoing, with an expansion cohort added to the study[18]. - The SON-080 program for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN) has been initiated, with a Phase 1b/2a trial started in October 2022[24]. - The SB211 study for SON-080 confirmed tolerability in initial patients, allowing progression to Phase 2 trials for neuropathy indications[24]. - The SON-1210 program, targeting solid tumors, has completed IND-enabling toxicology studies and is prepared for commercial development pending partnership activity[18]. - Phase 1 clinical trial for SON-1210 in solid tumors is expected to report topline efficacy data in H2 2025[28]. - The Phase 1b/2a trial of SON-1010 in combination with atezolizumab is ongoing, with no dose-limiting toxicities reported to date[72]. - The Sarcoma Oncology Center will conduct a Phase 1b/2a study of SON-1210 in pancreatic cancer, a significant unmet medical need[127]. Financials and Funding - The company reported net losses of approximately $16.0 million and $7.4 million for the fiscal years ended September 30, 2025 and 2024, respectively[205]. - As of September 30, 2025, the company had an accumulated deficit of approximately $133.7 million[205]. - The company has not yet commercialized any products or generated revenue from product sales[206]. - The company anticipates increased expenses as it continues to develop and conduct clinical trials for its product candidates[207]. - In the fourth quarter of 2025, holders exercised warrants to purchase 3,744,624 shares, generating gross proceeds of $11.2 million[191]. - In July 2025, the Company raised $2.0 million through a private placement of zero-interest convertible notes, convertible into 1,730,104 shares at $1.156 per share[192]. - The company raised an aggregate of $5.5 million in a private placement of Series 5 Convertible Preferred Stock, convertible at $1.25 per share[193]. - The November 2024 underwritten public offering generated net proceeds of approximately $4.2 million after deducting underwriting discounts and commissions[197]. - The company received a notice from Nasdaq on May 30, 2025, indicating non-compliance with the minimum stockholders' equity requirement of $2.5 million[198]. Partnerships and Collaborations - The company has entered into a licensing agreement with Alkem Laboratories for the development and commercialization of SON-080 in India[25]. - The Alkem Agreement, executed in October 2024, includes a $1.0 million upfront payment and potential milestone payments totaling up to $1.0 million for the commercialization of SON-080 in India[98]. - The New Life Agreement allows for the out-licensing of SON-080 for DPN in 10 ASEAN countries, with potential milestone payments totaling up to $19.0 million and royalties ranging from 12% to 30% on commercial sales[99]. - A collaboration agreement with Janssen Pharmaceuticals was announced to evaluate the efficacy of SON-1010, SON-1210, and SON-1410 in combination with Janssen's proprietary cell therapy assets[123]. Regulatory and Compliance - The company is subject to extensive government regulations regarding the research, development, and marketing of pharmaceutical products[143]. - The FDA typically inspects manufacturing facilities for compliance with cGMP requirements before approving a BLA[154]. - The FDA has 60 days for an initial review of a BLA submission, with a standard application review period of 12 months and 6 months for priority reviews[155]. - Orphan drug designation provides tax credits and market exclusivity for 7 years post-approval for products intended for rare diseases affecting fewer than 200,000 individuals in the U.S.[168]. - The accelerated approval pathway allows for products to be approved based on surrogate endpoints that predict clinical benefit, particularly for serious conditions[160]. Intellectual Property - The company has secured intellectual property protection for its proprietary manufacturing processes and formulations[34]. - The company has five issued patents and has filed applications in nine other major markets, with potential expiration dates ranging from 2038 to 2041[138]. - The company has received multiple patents for its Albumin Binding Domain Fusion Proteins, with U.S. Patent No. 11,028,166 issued on June 8, 2021, and estimated to expire on March 26, 2039[139]. - The company was granted U.S. Patent No. 12,006,361 on June 11, 2024, covering its product candidate SON-1210, a bifunctional version of IL-12 and IL-15[140]. Market Potential and Competition - The prevalence of diabetic peripheral neuropathy (DPN) is estimated to affect 50%-80% of the diabetic population, with projections indicating over 350 million people with diabetes by 2030[83]. - Current treatments for DPN primarily address pain, leaving significant unmet medical needs, which presents high commercial market potential for SON-080[85]. - The company faces significant competition from large pharmaceutical and biotechnology firms, which may have greater financial resources and expertise[119].

Exhibit 99.1 Contact: Ian Frazer Investor Relations Lennar Corporation (305) 485-4129 FOR IMMEDIATE RELEASE Lennar Reports Fourth Quarter and Fiscal 2025 Results 2025 Fourth Quarter Highlights 2025 Fiscal Year Highlights (more) • Net earnings per diluted share of $1.93; $2.03 excluding adjustments of: ◦ $123 million mark-to-market gains on technology investments, and ◦ $156 million one-time loss on previously announced Millrose Properties, Inc. ("Millrose") exchange offer • Net earnings of $490 million • Ne ...

Financial Performance - Net earnings for Q4 2025 were $490 million, or $1.93 per diluted share, down from $1.1 billion, or $4.06 per diluted share in Q4 2024[5]. - Total revenues for the three months ended November 30, 2025, were $9,367,609, a decrease of 5.8% from $9,946,888 in the same period of 2024[22]. - Homebuilding revenues decreased to $8,885,273 for the three months ended November 30, 2025, down 6.9% from $9,548,684 in 2024[25]. - Net earnings attributable to Lennar for the three months ended November 30, 2025, were $490,237, a decline of 55.3% compared to $1,096,214 in 2024[22]. - Homebuilding operating earnings fell to $717,960 for the three months ended November 30, 2025, down 52.0% from $1,495,383 in 2024[25]. - Financial Services operating earnings were $133 million in Q4 2025, down from $154 million in Q4 2024, due to lower volume and profit per loan[13]. - Financial Services operating earnings were $133,831 for the three months ended November 30, 2025, a decrease of 13.3% from $154,476 in 2024[25]. Home Sales and Orders - New orders increased 18% year over year to 20,018 homes in Q4 2025, while total revenues reached $9.4 billion[4]. - Deliveries for the full year 2025 were 82,583 homes, a 3% increase from 2024, with an average sales price of $386,000[6]. - The backlog of homes stood at 13,936 with a total dollar value of $5.2 billion[4]. - The company expects to deliver between 17,000 and 18,000 homes in Q1 2026, with an average sales price between $365,000 and $375,000[7]. - Total new orders for homes increased to 83,978 in 2025, up from 76,951 in 2024, representing a growth of approximately 9.5%[29]. - The total dollar value of new orders reached $31.95 billion in 2025, compared to $32.68 billion in 2024, indicating a decrease of about 2.2%[29]. - The average sales price for homes delivered decreased to $386,000 in the three months ended November 30, 2025, down from $430,000 in 2024[26]. - The average sales price of homes decreased to $380,000 in 2025 from $425,000 in 2024, a decline of approximately 10.6%[29]. - The average sales price for homes in the East region decreased to $362,000 in 2025 from $412,000 in 2024, a drop of approximately 12.1%[29]. Costs and Expenses - Homebuilding gross margin was 17.0% in Q4 2025, compared to 22.1% in Q4 2024, reflecting increased land costs and lower revenue per square foot[11]. - Selling, general and administrative expenses increased to 7.9% of home sales revenues in Q4 2025, up from 7.2% in Q4 2024[12]. - Homebuilding costs and expenses totaled $8,099,991 for the three months ended November 30, 2025, slightly down from $8,112,431 in 2024[25]. - The company reported a one-time loss of $156 million on the Millrose exchange offer included in the three months ended November 30, 2025[25]. Debt and Equity - Homebuilding debt rose significantly to $4.08 billion in 2025, compared to $2.26 billion in 2024, an increase of approximately 80.8%[35]. - Stockholders' equity decreased to $21.96 billion in 2025 from $27.87 billion in 2024, a decline of about 21.2%[35]. - The ratio of homebuilding debt to total capital increased to 15.7% in 2025 from 7.5% in 2024, indicating higher leverage[35]. - The company reported a net homebuilding debt of $643.36 million in 2025, compared to a net cash position of $2.40 billion in 2024[35]. Acquisitions - The company completed the acquisition of Rausch Coleman Homes in February 2025, enhancing its market position[9].

Financial Performance - Net sales for Q2 2026 were $327.5 million, an increase of 19% compared to Q2 2025[4] - Adjusted net earnings increased by 7% to $32.5 million, while net earnings decreased by 3% to $27.0 million[4] - Adjusted EBITDA grew 8% to $60.5 million, with operating income rising to $12.3 million from $3.5 million in the prior year[4][7] - Free cash flow improved by 15% to $39.1 million, up from $33.9 million in Q2 2025[4][11] - Operating cash flow for the quarter was $51.5 million, a 5% increase from $49.1 million in Q2 2025[4][11] - For the three months ended November 30, 2025, the GAAP net earnings were $27,328 thousand, with a diluted EPS of $0.55, while non-GAAP net earnings were $32,460 thousand, resulting in a diluted EPS of $0.65[35] - The adjusted EBITDA for the six months ended November 30, 2025, was $125,538 thousand, compared to $104,649 thousand for the same period in 2024, reflecting a year-over-year increase of approximately 20%[39] - Free cash flow for the three months ended November 30, 2025, was $39,086 thousand, up from $33,892 thousand in the same period of 2024, indicating a growth of about 15%[42] - The operating cash flow conversion for the six months ended November 30, 2025, was 148%, compared to 172% for the same period in 2024[42] Segment Performance - Building Products segment net sales increased by 31.9% to $207.5 million, driven by higher volumes and contributions from Elgen Manufacturing[14] - Consumer Products segment generated net sales of $119.9 million, a 2.7% increase over the prior year quarter[13] - The Building Products segment reported net sales of $207,528 thousand for the three months ended November 30, 2025, a 32.0% increase from $157,298 thousand in the same period of 2024[31] Assets and Liabilities - Total debt at quarter end was $305.3 million, with no borrowings under the revolving credit facility[12] - Total assets as of November 30, 2025, were $1,753,333 thousand, an increase from $1,695,152 thousand as of May 31, 2025[27] - Cash and cash equivalents decreased to $180,288 thousand from $250,075 thousand at the beginning of the period[29] Dividends and Shareholder Returns - The company declared a quarterly dividend of $0.19 per common share, payable on March 27, 2026[4] - Dividends declared per common share increased to $0.19 for the three months ended November 30, 2025, compared to $0.17 in the same period of 2024[25] Acquisitions and Investments - The company announced an agreement to acquire LSI Group for approximately $205 million, expected to close in January 2026[4][15] - The company’s investment in property, plant, and equipment for the three months ended November 30, 2025, was $12,432 thousand, compared to $15,161 thousand in the same period of 2024[42] Other Financial Metrics - Adjusted EBITDA margin for the consolidated results was 18.5% for the three months ended November 30, 2025, down from 20.5% in the same period of 2024[31] - The adjusted EBITDA margin for the three months ended November 30, 2025, was 18.5%, down from 20.5% in the same period of 2024[39] - The company reported a restructuring and other expense of $1,644 thousand for the three months ended November 30, 2025, which impacted the GAAP earnings[35] - The loss on the partial sale of investment in SES was $2,950 thousand for the three months ended November 30, 2025, affecting the overall earnings[35] - The net earnings attributable to controlling interest for the six months ended November 30, 2025, was $62,476 thousand, compared to $52,513 thousand in 2024, representing a year-over-year increase of approximately 19%[42]

Worthington Enterprises Reports Second Quarter Fiscal 2026 Results COLUMBUS, Ohio (December 16, 2025) – Worthington Enterprises Inc. (NYSE: WOR), a designer and manufacturer of market-leading consumer and building products that improve everyday life by elevating spaces and experiences, today reported results for its fiscal 2026 second quarter ended November 30, 2025. Recent Developments and Second Quarter Highlights (all comparisons to the second quarter of fiscal 2025): "We delivered solid financial result ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _____________ Commission File Number: 001-41532 HUDSON ACQUISITION I CORP. (Exact Name of Registrant as Specified in Its Charter) | Delaware | 86- 271284 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _____________ Commission File Number: 001-41532 HUDSON ACQUISITION I CORP. (Exact Name of Registrant as Specified in Its Charter) | Delaware | 86- 271284 ...